Amgen (NASDAQ: AMGN ) hasn't put as many eggs into the megablockbuster basket as Merck or Bristol-Myers Squibb, nor has it sought to utterly dominate a therapeutic area the way Biogen Idec
may dominate MS. What Amgen does offer, though, is a deep pipeline that
goes well beyond the much-discussed PCSK9 cholesterol market.
Biosimilar risk is a real threat to the current marketed portfolio, and
Amgen does not have much to offer within the hot immuno-oncology sector.
Less-appreciated opportunities in psoriasis and migraine could offer
upside as analysts start working those into their models, though.
Read the full article here:
3 Undervalued Amgen Growth Opportunities to Watch
No comments:
Post a Comment